ReviewFrontiers in immunology2026
From marrow memory to adverse ventricular remodeling: trained immunity after myocardial infarction.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial infarction [MI] triggers a sterile inflammatory response that is essential for necrotic-tissue clearance and scar formation and should normally subside as repair progresses. In a subset of patients, however, persistent myeloid activation accompanies progressive fibrosis, ventricular dilatation, and adverse remodeling long after the acute insult. Trained immunity may help explain this temporal mismatch by allowing myocardial injury to leave a durable functional bias in innate immune cells or their hematopoietic progenitors. Damage-associated molecular patterns, inflammatory cytokines, and sympathetic signals released after MI may reprogram bone-marrow hematopoiesis through metabolic and epigenetic mechanisms. Bone-marrow-derived cells can enter the circulation and injured myocardium directly; the spleen may provide an additional reservoir, hematopoietic niche, and amplification or deployment compartment rather than an obligatory intermediate. Resident and recruited cardiac macrophages then interpret this systemic input within the heart, where macrophage-fibroblast-extracellular matrix interactions influence scar composition, remote-zone fibrosis, ventricular geometry, and progression toward heart failure. This review follows a heart-hematopoietic-heart network and distinguishes direct MI-trained-immunity evidence from MI-specific bridging evidence, adjacent trained-immunity models, and downstream remodeling evidence. Individual components are supported to different degrees, but causal continuity from MI-induced hematopoietic memory to adverse ventricular remodeling has not yet been demonstrated. Defining where durable memory is established, how myeloid output reaches the heart, and when it becomes maladaptive may support phase-specific interventions that preserve early repair while limiting later inflammation and fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.